Literature DB >> 33355195

Kindlin3-Dependent CD11b/CD18-Integrin Activation Is Required for Potentiation of Neutrophil Cytotoxicity by CD47-SIRPα Checkpoint Disruption.

Panagiota Bouti1, Xi Wen Zhao2, Paul J J H Verkuijlen2, Anton T J Tool2, Michel van Houdt2, Nezihe Köker2,3, Mustafa Yavuz Köker3, Ozlem Keskin4, Sinan Akbayram5, Robin van Bruggen2, Taco W Kuijpers2,6, Hanke L Matlung2, Timo K van den Berg1,7.   

Abstract

The CD47-signal regulatory protein-alpha (SIRPα) immune checkpoint constitutes a therapeutic target in cancer, and initial clinical studies using inhibitors of CD47-SIRPα interactions in combination with tumor-targeting antibodies show promising results. Blockade of CD47-SIRPα interaction can promote neutrophil antibody-dependent cellular cytotoxicity (ADCC) toward antibody-opsonized targets. Neutrophils induce killing of antibody-opsonized tumor cells by a process identified as trogoptosis, a necrotic/lytic type of cancer cell death that involves trogocytosis, the antibody-mediated endocytic acquisition of cancer membrane fragments by neutrophils. Both trogocytosis and killing strictly depend on CD11b/CD18-(Mac-1)-mediated neutrophil-cancer cell conjugate formation, but the mechanism by which CD47-SIRPα checkpoint disruption promotes cytotoxicity has remained elusive. Here, by using neutrophils from patients with leukocyte adhesion deficiency type III carrying FERMT3 gene mutations, hence lacking the integrin-associated protein kindlin3, we demonstrated that CD47-SIRPα signaling controlled the inside-out activation of the neutrophil CD11b/CD18-integrin and cytotoxic synapse formation in a kindlin3-dependent fashion. Our findings also revealed a role for kindlin3 in trogocytosis and an absolute requirement in the killing process, which involved direct interactions between kindlin3 and CD18 integrin. Collectively, these results identified a dual role for kindlin3 in neutrophil ADCC and provide mechanistic insights into the way neutrophil cytotoxicity is governed by CD47-SIRPα interactions. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33355195     DOI: 10.1158/2326-6066.CIR-20-0491

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  11 in total

Review 1.  CD47/SIRPα axis: bridging innate and adaptive immunity.

Authors:  Anneloes van Duijn; Sjoerd H Van der Burg; Ferenc A Scheeren
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

2.  CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation.

Authors:  Françoise Gondois-Rey; Thomas Miller; Vladimir Laletin; Xavier Morelli; Yves Collette; Jacques Nunès; Daniel Olive
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

Review 3.  β2 Integrin Signaling Cascade in Neutrophils: More Than a Single Function.

Authors:  Panagiota Bouti; Steven D S Webbers; Susanna C Fagerholm; Ronen Alon; Markus Moser; Hanke L Matlung; Taco W Kuijpers
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

Review 4.  Neutrophil phenotypes and functions in cancer: A consensus statement.

Authors:  Daniela F Quail; Borko Amulic; Monowar Aziz; Betsy J Barnes; Evgeniy Eruslanov; Zvi G Fridlender; Helen S Goodridge; Zvi Granot; Andrés Hidalgo; Anna Huttenlocher; Mariana J Kaplan; Ilaria Malanchi; Taha Merghoub; Etienne Meylan; Vivek Mittal; Mikael J Pittet; Andrea Rubio-Ponce; Irina A Udalova; Timo K van den Berg; Denisa D Wagner; Ping Wang; Arturo Zychlinsky; Karin E de Visser; Mikala Egeblad; Paul Kubes
Journal:  J Exp Med       Date:  2022-05-06       Impact factor: 17.579

5.  Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.

Authors:  Dieke J van Rees; Panagiota Bouti; Bart Klein; Paul J H Verkuijlen; Michel van Houdt; Karin Schornagel; Anton T J Tool; David Venet; Christos Sotiriou; Sarra El-Abed; Miguel Izquierdo; Sébastien Guillaume; Cristina Saura; Serena Di Cosimo; Jens Huober; Rebecca Roylance; Sung-Bae Kim; Taco W Kuijpers; Robin van Bruggen; Timo K van den Berg; Hanke L Matlung
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 6.  Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.

Authors:  Leonie M Behrens; Timo K van den Berg; Marjolein van Egmond
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

7.  Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis.

Authors:  Ha-Ram Park; Seong-Eun Kim; Bhumsuk Keam; Hyewon Chung; Seung Hyeok Seok; Soyeon Kim; Miso Kim; Tae Min Kim; Junsang Doh; Dong-Wan Kim; Dae Seog Heo
Journal:  Sci Rep       Date:  2022-07-22       Impact factor: 4.996

Review 8.  The Role of Trogocytosis in the Modulation of Immune Cell Functions.

Authors:  Kensuke Miyake; Hajime Karasuyama
Journal:  Cells       Date:  2021-05-19       Impact factor: 6.600

9.  Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.

Authors:  Dieke J van Rees; Maximilian Brinkhaus; Bart Klein; Paul Verkuijlen; Anton T J Tool; Karin Schornagel; Louise W Treffers; Michel van Houdt; Arnon P Kater; Gestur Vidarsson; Andrew R Gennery; Taco W Kuijpers; Robin van Bruggen; Hanke L Matlung; Timo K van den Berg
Journal:  Blood Adv       Date:  2022-04-12

10.  G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Authors:  Paula Martinez Sanz; Dieke J van Rees; Hanke L Matlung; Godelieve A M Tytgat; Katka Franke; Lieke M J van Zogchel; Bart Klein; Panagiota Bouti; Hugo Olsman; Karin Schornagel; Ivana Kok; Ali Sunak; Kira Leeuwenburg; Ilse Timmerman; Miranda P Dierselhuis; Waleed M Kholosy; Jan J Molenaar; Robin van Bruggen; Timo K van den Berg; Taco W Kuijpers
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.